D. Lawrence

发表

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.

S. Pocock, H. Magnussen, P. Barnes, 2009, Pulmonary pharmacology & therapeutics.

Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies

Y. Gon, D. Lawrence, T. Ishii, 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.

J. Wedzicha, R. Buhl, D. Lawrence, 2015, Respiratory medicine.

Safety of indacaterol in the treatment of patients with COPD

Dave Singh, J. Donohue, B. Kramer, 2011, International journal of chronic obstructive pulmonary disease.

Efficacy of indacaterol in the treatment of patients with COPD.

C. Vogelmeier, P. Jones, N. Barnes, 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis

D. Lawrence, N. Wahlgren, J. Höijer, 2017, Journal of internal medicine.

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

H. Ghofrani, F. Grimminger, R. Barst, 2013, Circulation.

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

D. Mahler, R. Buhl, D. Lawrence, 2013, Pulmonary pharmacology & therapeutics.

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.

H. Kerstjens, D. Mahler, R. Buhl, 2015, Respiratory medicine.

Efficacy of Indacaterol 75 μg Once-Daily on Dyspnea and Health Status: Results of Two Double-Blind, Placebo-Controlled 12-Week Studies

E. Kerwin, B. Kramer, D. Lawrence, 2012, COPD.

Indacaterol therapy in patients with COPD not receiving other maintenance treatment.

M. Decramer, A. Rossi, D. Lawrence, 2012, Respiratory medicine.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

E. Kerwin, B. Kramer, D. Lawrence, 2011, Clinical therapeutics.

artery thrombosis Coronary artery thrombosis Myocardial infarction Brain stem infarction Embolic cerebral infarction Papillary muscle infarction Brain stem stroke Embolic stroke Post procedural myocardial Brain stem thrombosis Hemorrhagic cerebral infarction Post procedural stroke Carotid arterial e

Dave Singh, J. Donohue, B. Kramer, 2011 .

Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial

I. Agache, T. Kamei, Thomas Lehmann, 2021, Respiratory Research.

Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.

L. Hang, S. H. Lee, Y. Fukuchi, 2012, Respiratory medicine.

When is a seamless study desirable? Case studies from different pharmaceutical sponsors

Andrew Stone, David Lawrence, Marc Vandemeulebroecke, 2014, Pharmaceutical statistics.

Effect of indacaterol on exercise endurance and lung hyperinflation in COPD.

Richard Casaburi, R. Casaburi, D. O’Donnell, 2011, Respiratory medicine.

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.

Hyuk-Jae Chang, H. Ghofrani, R. Barst, 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

M. Decramer, P. Frith, R. Dahl, 2013, The Lancet. Respiratory medicine.

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

M. Decramer, R. Dahl, S. Korn, 2013, Respiratory medicine.

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

Didier Renard, Michael Looby, D. Stanski, 2011, Respiratory research.

Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.

E. Bleecker, C. Brightling, S. Wenzel, 2020, The Lancet. Respiratory medicine.

Efficacy,Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease

R. Woessner, Soichiro Matsushima, B. Kramer, 2011, Clinical drug investigation.

Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)

E. Kerwin, M. Castro, D. Lawrence, 2021, EClinicalMedicine.

Approaches for Optimal Dose Selection for Adaptive Design Trials

Frank Bretz, David Lawrence, F. Bretz, 2014 .

INHANCE: An Adaptive Confirmatory Study with Dose Selection at Interim

Frank Bretz, David Lawrence, Stuart J. Pocock, 2014 .

The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.

R. Dahl, H. Kerstjens, G. Deslée, 2015, Pulmonary pharmacology & therapeutics.

Imatinib Safety And Efficacy: Interim Analysis Of IMPRES Extension Study In Patients With Pulmonary Arterial Hypertension

H. Ghofrani, R. Barst, H. Klose, 2012, ATS 2012.

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

M. Decramer, P. Frith, R. Dahl, 2013, The Lancet. Respiratory medicine.

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

M. Decramer, R. Dahl, S. Korn, 2013, Respiratory medicine.